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Stroke and death after carotid endarterectomy and
carotid artery stenting with and without high risk
criteria
Kristina A. Giles, MD, Allen D. Hamdan, MD, Frank B. Pomposelli, MD, Mark C. Wyers, MD, and
Marc L. Schermerhorn, MD, Boston, Mass
Objective: Centers for Medicare and Medicaid Services (CMS) reimbursement criteria for carotid artery stenting (CAS)
require that patients be high surgical risk or enrolled in a clinical trial. This may bias comparisons of CAS and carotid
endarterectomy (CEA). We evaluate mortality and stroke following CAS and CEA stratified by medical high risk criteria.
Methods: The Nationwide Inpatient Sample (2004-2007) was queried by ICD-9 code for CAS and CEA with diagnosis of
carotid artery stenosis. Medical high risk criteria were identified for each patient including patients undergoing a coronary
artery bypass and/or valve repair (CABG/V) during the same admission. Symptom status was defined by history of stroke,
transient ischemic attack (TIA), and/or amarosis fugax. The primary outcome was postoperative death, stroke (complication
code 997.02), and combined stroke or death, stratified by high risk vs non-high risk status and symptom status.
Results: Patient totals of 56,564 (10.5%) CAS and 482,394 (89.5%) CEA were identified. Half of the patients in each
group were high risk. CABG/V was performed less commonly with CAS than CEA (2.8% vs 4.0%, P < .001). Patients
undergoing CAS were more likely symptomatic than those undergoing CEA (13.1% vs 9.4%, P < .001). Mortality was
higher after CAS than CEA for both high risk and non-high risk patients. Stroke was also higher after CAS for both high
risk and non-high risk patients. Combined stroke or death was higher after CAS again for both high risk (asymptomatic
1.5% vs 1.2%, P < .05, symptomatic 14.4% vs 6.9%, P < .001) and non-high risk (asymptomatic 1.8% vs 0.6%, P < .001,
symptomatic 11.8% vs 4.9%, P < .001). Combined stroke or death for patients undergoing CABG/V during the same
admission was similar for CAS and CEA (4.8% vs 3.2%, P  .19). Multivariate predictors of combined stroke or death
adjusted for age and gender included CAS vs CEA (odds ratio [OR] 2.4, P< .001), symptom status (OR 6.8, P< .001),
high risk (OR 1.6, P < .001), and earlier year of procedure (OR 1.1, P < .01).
Conclusions: In the United States from 2004 to 2007, CAS has a higher risk of stroke and death than CEA after
adjustment for medical high risk criteria. Further analysis with prospective assessment of risk factors is needed to guide
appropriate patient selection for CEA and CAS in the general population. (J Vasc Surg 2010;52:1497-504.)Carotid artery stenting (CAS) emerged as an alternative
to carotid endarterectomy (CEA) for carotid artery stenosis
in 1989.1-3 Since that time, with evolving technology and
experience, comparative studies have shown varying results.
Randomized trials and registries have also yielded conflict-
ing results.1-13 The Centers for Medicare and Medicaid
Services (CMS) criteria for reimbursement of CAS man-
dates that patients be “high risk for CEA” with symptom-
atic70% stenosis unless enrolled in a clinical trial. Medical
high risk criteria are predominantly cardiac conditions in-
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doi:10.1016/j.jvs.2010.06.174cluding recentmyocardial infarction, severe congestive heart
failure (CHF), need for coronary revascularization or valve
repair within 30 days, and unstable angina in addition to
severe pulmonary and end-stage renal disease (Table I).14
Therefore, comparisons of the two techniques may be bi-
ased by over representation of high risk and symptomatic
patients in the CAS cohort. For this study, we compare
outcomes of CAS and CEA accounting for symptom status
and high risk status.
METHODS
Database. The Nationwide Inpatient Sample (NIS)
from 2004 to 2007 was used for this study. The NIS,
maintained through the Healthcare Cost and Utilization
Project of the Agency for Healthcare Research andQuality,
currently includes over 8 million annual hospitalizations
from 40 states. The sampling frame allows the NIS to
represent approximately 90% of all hospitalizations, making
it the largest all-payer inpatient database in the United
States.15
Data retrieval. The NIS was queried for patient selec-
tion using diagnosis and procedure codes from the Inter-
national Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) system codes. The procedure
code for CAS was introduced in October of 2004 and, at
the time of study initiation, NIS data were available
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codes were used to identify patients undergoing either
carotid endarterectomy (38.12) or carotid artery stenting
(00.61, 00.63) for carotid artery stenosis (443.10, 443.11,
443.30, 443.31). Additionally, patients having coronary
artery bypass (CABG) (36.11-36.16), cardiac valve repair
(35), percutaneous coronary artery intervention (PCI)
(00.66, 36.01, 36.02, 36.05, 36.06, 36.07), or a diagnos-
tic cardiac catheterization (37.21, 37.22, 37.23) during the
same hospital stay were identified. Cardiac procedures were
recorded in a hierarchical schema (in order listed) to pre-
vent dual counting. PCI and diagnostic cardiac catheteriza-
tions were included for descriptive purposes only and did
not factor into high risk status. Patients admitted with a
primary diagnosis of an acute myocardial infarction (410)
were excluded from analysis as were those 18 years of age.
Patients with symptomatic carotid stenosis were identified by
ICD-9 diagnosis codes of transient ischemic attack (TIA)
(435 or 781.4), amarosis fugax (362.34 or 368.12), or stroke
(433.11, 433.31, 433.91, 434.01, 434.11, 434.91).
ICD-9 diagnosis codes were also used to identify co-
morbid conditions. Age, gender, and race were recorded as
demographic variables. General comorbid conditions were
recorded as well as those that would qualify the patient for
CMS medical high risk (Table I). High risk as determined
by available ICD-9 coding was included as a composite
variable for comparison and adjustment of outcomes. We
also performed analysis of individual high risk criteria to
determine relative impact. Patients without any of these
factors were classified as non-high risk patients. Primary
outcomes were death, stroke (997.02), and combined
stroke or death occurring during the hospitalization. Sec-
ondary outcomes included complications, hospital length
of stay, and hospital costs. The complications recorded
were global complications (996-999), acute renal failure
(584), and cardiac complications (997.1).
Statistical analysis. Queries of the NIS data were
performed with SAS (version 9.1, SAS Institute, Cary, NC)
and all statistical analyses were performed using STATA
Table I. CMS high risk criteria
Medical high risk ICD-9 Code
Age 80a
Renal failurea 585.3-585.9, 586, V42.0,
V 45.1, V56.0-V56.32,
V6.8, V45.11-V45.12
Severe chronic lung diseasea 490-492.8, 493, 494-
494.1, 495-505, 506.4
Recent myocardial infarctiona 412
LV ejection fraction 30%
Requirement for aortocoronary
bypass or cardiac valve surgery
within 30 daysa
36.11-36.14, 35
Unstable anginaa 411.1
Class III/IV congestive heart failurea 428
CMS, Centers for Medicare and Medicaid Services.
aIdentified within the current study by ICD-9 codingstatistical computing software (Stata Statistical Software:Release 8.2; StataCorp LP, College Station, Tex). Popula-
tion estimates were calculated based upon the weighted
discharge values within the NIS. All presented information
reflects weighted estimates. Comparisons between CEA
and CAS as well as carotid procedures with and without
CABG/valve surgery were performed using Student t test
for (parametric data) or Wilcoxon rank-sum (nonparamet-
ric data) for continuous measures and 2 tests for categor-
ical variables. Univariate logistic regression was used to
assess significance of predictive variables for stroke or death
as well as mortality alone. Multivariate logistic regression
analysis was performed by backwards selection of variables
obtaining significance at the P  .1 level on univariate
analysis with adjustment for high risk criteria. Statistical
significance was determined by a P value of .05.
RESULTS
There were 56,564 (10.5%) patients who underwent
CAS, and 482,394 (89.5%) patients who underwent CEA
from 2004-2007. CAS increased from 8.5% of carotid
revascularizations in 2004 (October–December) to 12.3%
in 2007 with the largest percentage in 2006 at 16.1% (P 
.001). CABG/V was performed more frequently during
the same hospitalization with CEA (4.0%) than CAS (2.8%,
P  .001) (Fig). Comparatively, a greater number of CAS
patients had a PCI (1.0% vs 0.4%, P .001) or a diagnostic
cardiac catheterization (3.1% vs 1.7%, P  .001).
Half of all patients for both methods of carotid repair
were high risk (CAS 50.5% vs CEA 50.8%, P .58) (Table
II). Patients undergoing CAS had higher rates of CHF and
chronic renal failure and lower rates of chronic obstructive
pulmonary disease (COPD) and urgent heart surgery
(CABG/V). Age was similar although statistically signifi-
cant between the two groups (CAS 69.8  11.3 years vs
CEA 71.1  9.5 years, P  .001) and the proportion of
patients equal to or greater than 80 years was similar (19.7%
vs 20.1%, P .69). There was a slightly greater proportion
of males undergoing CAS (60.2%) compared with CEA
overall (57.5%, P .001); however, among patients receiv-
Fig. Cardiac procedures performed during hospitalization for ca-
rotid endarterectomy or carotid artery stenting from October
2004 through 2007.ing concurrent CABG/valve, there was a greater propor-
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CAS (57.9%, P  .05).
There was a greater proportion of symptomatic patients
undergoing CAS compared with CEA (13.1% vs 9.4%, P.
001) (Table II). This trend persisted although was not
statistically significant for patients undergoing concurrent
CABG/valve (12.0% vs 8.8%, P .06). Symptom status for
patients undergoing PCI (14.3% vs 13.5%, P  .82) or
diagnostic catheterization (15.5% vs 16.4%) was similar for
CAS and CEA.
Stroke or death
In the overall cohort, combined stroke or death was
higher following CAS (3.1%) than CEA (1.4%, P  .001)
(Table III). This was true for both symptomatic (13.1% vs
5.9%, P  .001) and asymptomatic patients (1.6% vs 0.9%,
P .001). Combined stroke or death for patients with high
risk was also higher after CAS than CEA (3.2% vs 1.8%, P
.001). Again, this was significant for both symptomatic
(14.4% vs 7.0% P .001) and asymptomatic patients (1.6%
vs 1.2%, P  .05). For non-high risk patients, combined
stroke or death rates were also higher after CAS overall
(3.1% vs 1.0%, P  .001) and for symptomatic (11.8% vs
4.9%, P  .001) and asymptomatic patients (1.8% vs 0.6%,
P  .001).
In contrast, patients undergoing concurrent CABG/
valve had similar combined stroke or death rates following
CEA and CAS (4.8% vs 3.2%, P  .19) overall. However,
stroke or death was higher with CEA in asymptomatic
patients (CEA 3.8% vs CAS 1.5%, P  .05) but not symp-
tomatic patients (CEA 15.4% vs CAS 15.7%, P  .95).
In those with age 80, mortality, stroke, and com-
bined stroke or death were higher after CAS for symptom-
atic patients (6.6% vs 2.7%, 9.0% vs 4.6%, and 14.7% vs
Table II. Concurrent cardiac procedures, symptom
status, and demographics of patients undergoing carotid
repair from the nationwide inpatient sample 2004-2007
CAS CEA
P
value
N  56,564,
10.5%
N  482,394,
89.5%
High risk 28,573, 50.5% 244,991, 50.8% .58
Age 80 years 11,168, 19.7% 96,815, 20.1% .41
Renal failure 4218, 7.5% 22,925, 4.8% .001
Chronic lung
disease 10,546, 18.6% 104,396, 21.6% .001
Prior myocardial
infarction 5840, 10.3% 52,160, 10.8% .11
Congestive heart
failure 6166, 10.9% 35,346, 7.3% .001
CABG/valve 1592, 2.8% 19,217, 4.0% .001
Unstable angina 730, 1.3% 4,703, 1.0% .01
Symptomatic 7438, 13.1% 45,499, 9.4% .001
Age (mean  SD) 69.8  11.3 71.1  9.5 .001
Male 24,306, 60.2% 210,805, 57.5% .001
CABG, Coronary artery bypass; CAS, carotid artery stenting; CEA, carotid
endarterectomy.6.7%, respectively, P  .001 all). In asymptomatic octoge-narians undergoing CAS vs CEA, mortality was similar
(0.6% vs 0.6%, P  .92), stroke was higher (1.1% vs 0.7%,
P .05) and combined stroke or death was similar (1.5% vs
1.2%, P .16).
Multivariate analysis
Stroke or death. On multivariate analysis, CAS was
associated withmore than double the risk of stroke or death
compared with CEA (odds ratio [OR] 2.4, 95% confidence
interval [CI] 2.1-2.8) (Table IV, A). Other predictors
included symptomatic status (OR 6.8, 95% CI 6.1-7.6) and
high risk (OR 1.6, 95% CI 1.4-1.8). Later year of proce-
dure was associated with lower event rates (OR 0.9, 95% CI
0.8-0.97). When individual high risk criteria were analyzed
separately, CABG/valve was the strongest predictor of
stroke or death (OR 5.4, P .001) followed by CHF (OR
2.2, P  .001), renal failure (OR 1.7, P  .001), age 80
(OR 1.2, P .05), and chronic lung disease (OR 1.2, P
.05) (Table IV, B). Patients with a prior myocardial infarc-
tion had a lower risk of stroke or death (OR 0.7, P .001)
and unstable angina showed no difference (OR 1.0, P 
.95).
Death. Predictors of mortality were CAS (OR 3.1,
95% CI 2.5-3.8), high risk (OR 2.6, 95% CI 2.2-3.1), and
symptomatic patients (OR 5.3, 95% CI 4.4-6.3) (Table V,
A). Analysis of individual high risk factors demonstrated
similar results to those for stroke and death (Table V, B).
Stroke. CAS was also predictive of stroke (OR 2.1,
95% CI 1.7-2.5) as were symptom status (OR 7.6, 95% CI
6.7-8.7) and high risk (OR 1.3, 95% CI 1.2-1.5), while
later year of procedure was again protective (OR 0.9, 95%
CI 0.8-0.99) (Table VI, A). Analysis of individual high risk
criteria showed only concomitant CABG/valve (OR 3.7
95% CI 2.8-4.9) and CHF (OR 1.4, 95% CI 1.1-1.7) to be
predictive (Table VI, B).
In a subgroup analysis of only patients undergoing
concurrent CABG/valve, carotid repair type was no longer
predictive of stroke or death (CAS vs CEA OR 1.4, 95% CI
0.6-3.0) (Table VII). In this group, only symptom status
(OR 6.1, 95% CI 4.0-9.3) and the individual comorbidities
of CHF (OR 3.5, 95% CI 1.8-6.7) and chronic renal failure
(OR 2.0, 95 CI 1.2-3.3) were predictive of stroke or death
after adjustment for age and gender. Year of procedure was
not associated with outcome in this group.
In a separate subgroup analysis of symptomatic patients
only, CAS (OR 2.6, 95% CI 2.1-3.2, P  .001) and high
risk status (OR 1.5, 95% CI 1.2-1.7, P  .001) were both
predictive of increased stroke or death.
Secondary outcomes
Global complications were more common after CAS
than CEA for carotid revascularization alone (13.6% vs
9.6%, P  .001) but were less common after CAS for
concurrent carotid and CABG/valve procedures (20.8% vs
27.2%, P  .05) (Table III). Cardiac complications were
similar between repair types for the overall group (CAS
1.9% vs CEA 1.8%) but were lower after CAS for patients
undergoing CABG/valve (4.2% vs 8.1%, P .05). Length
omy; S
JOURNAL OF VASCULAR SURGERY
December 20101500 Giles et alof stay was longer after CAS overall (2 days vs 1 day, P 
.001) and for high risk patients (2 days vs 1 day, P .001)
but similar if concurrent CABG/valve (11 days vs 12 days,
P .50). Hospital costs were higher for CAS than CEA for
all subgroups.
DISCUSSION
This study, using a large population-based database
from recent years, shows that when accounting for symp-
tom status and medical high risk criteria (including concur-
rent cardiac procedures), carotid stenting has a higher risk
of combined stroke or death, as well as death and stroke
alone compared with carotid endarterectomy in the general
US population. High risk status was associated with worse
outcome for CEA compared with non-high risk. Outcomes
with CAS, however, were not improved in high risk patients
compared with CEA.
CMS reimbursement for CAS for symptomatic high
risk patients was based in part on the results of a random-
ized trial showing similar stroke and death rates but a lower
rate of a combined end point of stroke, death, or MI with
CAS vs CEA9 as well as on a historic control made up of
patients undergoing concomitant CEA and CABG.16 Our
study suggests that these results are not reflective of current
national outcomes. The SAPPHIRE trial showed a stroke
or death rate of 5.5% for CAS vs 8.5% for CEA (P.36) at
1 year (30-day mortality 1.2% vs 2.5%, P .39 and 30-day
Table III. Outcomes following carotid repair and concurr
2004-2007
CAS
N  56,564, 10.5
Stroke or death 1780, 3.2%
-High risk 906, 3.2%
-Non-high risk 874, 3.1%
Sx | Asx
973, 13.1% | 807, 1
-High risk 14.4% | 1.5%
-Non-high risk 11.8% | 1.8%
Mortality 846, 1.5%
-High risk 430, 1.5%
-Non-high risk 416, 1.5%
Sx | Asx
448, 6.0% | 398, 0
-High risk 6.8% | 0.7%
-Non-high risk 5.3% | 0.9%
Stroke 1093, 1.9%
-High risk 560, 2.0%
-Non-high risk 533, 1.9%
Sx | Asx
603, 8.1% | 490, 1
-High risk 8.8% | 1.0%
-Non-high risk 7.5% | 1.0%
Global complications (high risk) 13.6% (14.9%)
Cardiac complications (high risk) 1.9% (2.2%)
Acute renal failure (high risk) 1.9% (2.9%)
LOS [median, range] 1 [0-258]
Total cost [median, range] $12,406 (46-319,1
Asx, Asymptomatic; CAS, carotid artery stenting; CEA, carotid endarterectstroke 3.6% vs 3.1%, P  .77).9Subsequent randomized trials in average risk patients
have shown conflicting results. They have shown either
increased stroke and death with CAS or similar results
between the two repair methods but with a failure to meet
non-inferiority.16,10-12,17 The recently presented CREST
trial showed similar rates of stroke, death, and MI in
symptomatic and asymptomatic patients with very low
event rates in both the CAS and CEA groups. Stroke was
lower with CEA while MI was lower with CAS. While this
demonstrates the efficacy of CAS in selected patients
treated by experienced physicians and supports the prior
literature demonstrating a lower stroke rate with CEA, our
study suggests that similar results may not be duplicated
nationally.17 As an important note, there were strict criteria
for interventionalists participating in CREST. They re-
quired prior performance of at least 35 carotid stent cases
with a subsequent roll-in phase where 10 CAS were per-
formed under supervision. Only physicians with adequate
outcomes were invited to participate in the study.13
Wennberg et al previously demonstrated that mortality
after CEA was substantially higher in Medicare patients
compared with patients enrolled in NASCET and ACAS,
even if their CEA was performed in the same institutions
participating in the trials.18 Our findings suggest that this
increased mortality may be due to procedures performed in
select high risk patients. Our national analysis suggests that
mortality rates with CEA in non-high risk patients com-
ardiac procedures from the nationwide inpatient sample
CEA
P valueN  482,394, 89.5%
6670, 1.4% .001
4304, 1.8% .001
2366, 1.0% .001
Sx | Asx
2698, 5.9% | 3973, 0.9% .001 | .001
6.9% | 1.2% .001 | .05
4.9% | 0.6% .001 | .001
2432, 0.5% .001
1941, 0.8% .001
491, 0.2% .001
Sx | Asx
814, 1.8% | 1618, 0.4% .001 | .001
2.5% | 0.6% .001 | .28
1.0% | 0.1% .001 | .001
4727, 1.0% .001
2723, 1.1% .001
2004, 0.8% .001
Sx | Asx
2099, 4.6% | 2628, 0.6% .001 | .001
5.0% | 0.7% .001 | .05
4.2% | 0.5% .001 | .001
9.6% (11.9%) .001 (.001)
1.8% (2.4%) .27 (.35)
1.3% (2.3%) .001 (.01)
2 [0-120] .001
$7213 (13-459,915) .001
x, symptomatic.ent c
%
.6%
.8%
.0%
07)pares favorably with NASCET (1.0% vs 0.6%) and ACAS
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able.19,20 CEA in high risk patients shows increased mor-
tality and stroke/death compared with average risk; how-
Table IV. Multivariate predictors of stroke or death after
carotid repair (adjusted for age/gender)
A, Composite medical high risk criteria
Predictors of combined stroke or death
OR 95% CI P value
Carotid stent vs endarterectomy 2.4 2.1-2.8 .001
Symptomatic 6.8 6.1-7.6 .001
High risk 1.6 1.4-1.8 .001
Year of procedure 0.9 0.8-0.97 .01
B, Individual high risk criteria
Predictors of combined stroke or death
(individual high risk criteria)
Carotid stent vs endarterectomy 2.5 2.2-2.9 .001
Symptomatic 7.0 6.3-7.9 .001
High risk
Age 80 years 1.2 1.03-1.3 .05
Renal failure 1.7 1.4-2.1 .001
Chronic lung disease 1.2 1.04-1.3 .05
Prior myocardial infarction 0.7 0.5-0.8 .001
Congestive heart failure 2.2 1.9-2.5 .001
CABG/valve 5.4 4.4-6.7 .001
Unstable angina 1.0 0.7-1.4 .95
Year of procedure 0.9 0.8-0.95 .01
CABG, Coronary artery bypass; CI, confidence interval; OR, odds ratio.
Table V. Multivariate predictors of death after carotid
repair (adjusted for age/gender)
A, Composite medical high risk criteria
Predictors of death
OR 95% CI P value
Carotid stent vs endarterectomy 3.1 2.5-3.8 .001
Symptomatic 5.3 4.4-6.3 .001
High risk 2.6 2.2-3.1 .001
Year of procedure 0.9 0.8-0.99 .05
B, Individual high risk criteria
Predictors of death (individual high risk criteria)
Carotid stent vs endarterectomy 3.2 2.6-4.0 .001
Symptomatic 5.3 4.5-6.4 .001
Female 0.8 0.7-0.99 .05
High risk
Age 80 years 1.4 1.2-1.7 .001
Renal failure 2.6 2.0-3.4 .001
Chronic lung disease 1.4 1.2-1.8 .001
Prior myocardial infarction 0.5 0.3-0.7 .001
Congestive heart failure 3.5 2.9-4.3 .001
CABG/valve 7.1 5.4-9.3 .001
Unstable angina 0.6 0.4-1.1 .10
Year of procedure 0.9 0.8-0.96 .01
CABG, Coronary artery bypass; CI, confidence interval; OR, odds ratio.ever, CAS outcomes were worse than CEA for both highand average risk patients. It is certainly possible that our
high risk criteria may not detect true high risk status in
some CAS patients and may also overestimate high risk in
CEA patients. The lack of specificity of ICD-9 coding
unfortunately means our definition of high risk is overesti-
mated in general. However, CEA in high risk patients was
associated with improved outcome compared with CAS in
non-high risk patients. While these limitations hinder our
ability to draw strong conclusions about the safety of CAS,
the strongest conclusion to be drawn is that average risk
patients undergoing CEA fare reasonably well.
These data suggest that further careful analysis should
be made to be certain that the efficacy demonstrated in
randomized trials with carefully selected patients being
treated by highly trained physicians is translated into effec-
tiveness with similar results in broad general practice.
Prior analyses using the NIS database as well as the SVS
registry did not account for high risk status.21-24 Our
Table VI. Multivariate predictors of stroke after carotid
repair (adjusted for age/gender)
A, Composite medical high risk criteria
Predictors of stroke
OR 95% CI P value
Carotid stent vs endarterectomy 2.1 1.7-2.5 .001
Symptomatic 7.6 6.7-8.7 .001
High risk 1.3 1.2-1.5 .001
Year of procedure 0.9 0.8-0.99 .05
B, Individual high risk criteria
Predictors of stroke (individual high risk criteria)
Carotid stent vs endarterectomy 2.1 1.8-2.5 .001
Symptomatic 7.8 6.8-8.9 .001
High risk
Age 80 years 1.0 1.0-1.3 .65
Renal failure 1.0 0.7-1.3 .84
Chronic lung disease 1.1 0.9-1.3 .29
Prior myocardial infarction 0.8 0.7-1.1 .14
Congestive heart failure 1.4 1.1-1.7 .01
CABG/valve 3.7 2.8-4.9 .001
Unstable angina 1.3 0.9-2.0 .20
Year of procedure 0.9 0.8-0.99 .05
CABG, Coronary artery bypass; CI, confidence interval; OR, odds ratio.
Table VII. Multivariate predictors of stroke or death for
patients undergoing carotid repair and CABG/valve
(adjusted for age/gender)
OR 95% CI P value
Carotid stent vs endarterectomy 1.4 0.6-3.0 .46
Symptomatic 6.1 4.0-9.3 .001
Congestive heart failure 3.5 1.8-6.7 .01
Chronic renal failure 2.0 1.2-3.3 .01
Year of procedure 0.9 0.7-1.1 .32
CABG, Coronary artery bypass; CI, confidence interval; OR, odds ratio.analysis demonstrates the disparate outcomes in these
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for this stratification for any future comparisons of these
procedures. The NIS database is hampered by a question-
able ability to discriminate preoperative stroke from a post-
operative complication and the potential to underestimate
preoperative symptomatic status. We defined symptom sta-
tus by ICD-9 coding for prior stroke, TIA, or amarosis
fugax; however, the proportion is lower than institutional
and clinical trials, which likely have more accurate clinical
assessments. Using the NIS, McPhee et al found 92.1% of
carotid procedures were performed for asymptomatic dis-
ease23 while Vogel et al found a3% symptomatic propor-
tion using differing algorithm to define symptom status.21
Comparatively, Kang et al reported a 43% symptomatic rate
in nearly 4000 patients from the National Surgical Quality
Improvement Program from 2005-2006.25 However, re-
sults from early NSQIP data may not reflect what is occur-
ring nationally.
The ARCHeR trial for high risk patients undergoing
CAS showed a 30-day stroke or death rate of 11.6% for
symptomatic patients and 5.4% for asymptomatic pa-
tients.26 This high event rate in symptomatic patients is
similar to the national outcomes that we found in our
analysis (14.4% in-hospital stroke or death). We found also,
however, that non-high risk patients also had a high com-
bined stroke and death rate at 11.8% whereas asymptomatic
patients had significantly lower event rates (1.5% high risk,
1.8% non-high risk), showing that symptom status confers
the greatest risk in patients undergoing carotid stenting.
Symptomatic patients older than 80 years did particularly
poorly with combined stroke and death rates of 14.7% after
CAS and 6.7% after CEA. Careful patient selection should
be employed when considering carotid procedures in this
age group.
There was an increased likelihood of CAS patients to be
symptomatic. This is likely attributable to CMS reimburse-
ment requirements as well. Evaluation of patients pre- and
postoperatively may be more accurate for CAS given that a
detailed neurologic evaluation is required by CMS. This
may more accurately identify symptomatic patients preop-
eratively and may detect more minor strokes postopera-
tively. However, this should not impact the analysis of
mortality. Adjustment for symptom status may in fact bias
mortality evaluation in favor of stenting.
Our analysis showed that for patients undergoing con-
current carotid repair and CABG/valve surgery, CAS did
not have an increased risk of stroke or death compared with
CEA. Concurrent CABG/valve was performed in 3.9% of
carotid revascularization procedures. It is unlikely that
those patients undergoing concurrent carotid and cardiac
surgery would have differing procedural risk patterns com-
pared with those not undergoing cardiac surgery. CAS is
typically performed in a separate setting prior to CABG,
therefore, those dying after CAS would not be detected in
this analysis. Additionally, patients with a major CVA after
CAS are likely to have CABG deferred, therefore, there is
inherent bias against CEA, which may more commonly be
performed in the same setting as CABG/valve. The use ofaspirin, plavix, and statins may be more likely in patients
undergoing a CABG and blood pressure may be better
optimized; however, how this impacts CEA vs CAS differ-
entially is unknown. While many publications regarding
CEA and CABG exist, information specifically about com-
bined CAS and CABG is scarce and mostly limited to single
institution studies.5,16,28 Naylor et al recently systemati-
cally reviewed all published studies of staged CAS and
CABG and found a 30-day stroke or death rate of 9.1%with
an overall mortality of 5.5%.5 Another recent systematic
review found a 30-day stroke and death rate of 12.3% and
mortality of 7.6% for CAS andCABG.27 This is significantly
higher than our current results of 3.2% stroke/death and
1.6% mortality for in-hospital CAS/CABG outcomes. Ti-
maran et al used the NIS from the years 2000-2004 (prior
to CAS specific ICD-9 codes), spanning the time before the
current study, to compare CAS and CABG with CEA and
CABG. At that time, only 3.3% (887) of combined cardiac
and carotid procedures were CAS compared with 96.7%
CEA. They found an in-hospital stroke and death rate after
CAS and CABG of 6.9% and after CEA and CABG of 8.6%
but no difference in predictive risk on multivariate analy-
sis.28 Given the substantially higher rates of adverse events
in this group of patients, it seems prudent to analyze their
outcomes separately. Similarly, improved stratification of
outcomes within other high risk subgroups appears war-
ranted.
We adjusted outcomes based upon medical high risk
criteria but not for anatomic high risk, which is unattainable
in the NIS data. Most of these have been shown to increase
risk of local complications such as infection and nerve injury
but not stroke or death.29,30 Failure to detect anatomic
high risk as an indication for CAS is unlikely to affect these
results. Contralateral occlusion has been shown to increase
risk of CEA in large studies, but little data exist to evaluate
the impact on CAS outcomes.31-32
Outcomes improved with time as shown in our multi-
variate analyses. This was true for the overall group as well
as for CAS and CEA independently. With improving tech-
nology and increasing practitioner expertise, this is ex-
pected for CAS; however, it was a surprising finding with
CEA. This may indicate that as CAS becomes more widely
used, fewer high risk patients are having CEA performed,
thus improving the results of CEA over time.
We included PCI and diagnostic cardiac catheteriza-
tions in our study as coexisting cardiac procedures. There
was a greater number of both performed during the same
admission as CAS compared with CEA, however, which
may indicate that these catheter-based procedures are done
prior to or with CAS while they may more likely reflect
postoperative cardiac complications after CEA.
The limitations of this study are primarily due to the
nature of the database as an administrative data set some of
which are noted above. Additionally, the database is limited
to inpatient outcomes only, therefore, we cannot identify
staged carotid and cardiac procedures if a patient was
discharged between procedures. We also cannot extend
outcomes to 30-day results as much of the prior literature
JOURNAL OF VASCULAR SURGERY
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occur after hospital discharge, so this is an important dis-
tinction.24
The data set has no information on severity of stenosis
or anatomic risk factors that may predispose a patient to
adverse outcomes with either repair method. For preoper-
ative data, we cannot determine severity of prior stroke,
laterality, frequency of symptoms, or the temporal relation-
ship of symptoms and surgical repair.
CONCLUSION
In the overall population, CAS is associated with a
higher risk of stroke or death, death, and stroke compared
with CEA for carotid stenosis even after adjustment for
symptom status and medical high risk criteria. As more
randomized trials define the efficacy of CAS relative to
CEA, additional population-based analyses with well de-
fined high risk criteria are needed to be certain that accept-
able results are obtainable in the general population. Fur-
ther work is also needed to define the appropriate role of
either revascularizationmethod in those with specified high
risk criteria.
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